Nonalcoholic fatty liver disease (NAFLD ... and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

One liver cancer, hepatocellular carcinoma (HCC), is associated ... Both CLD subtypes showed lower gene expression associated with fatty acid metabolism, and Subtype 2 showed higher fatty acid ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal ...

It is crucial to recognize that patients with nonalcoholic fatty liver disease (NAFLD)-related HCC may not be ideal candidates for immunotherapy, given conflicting outcomes in NASH progression and HCC ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

With no noticeable symptoms until it progresses to irreversible conditions like cirrhosis or hepatocellular carcinoma (HCC), fatty liver remains a silent killer. Worse still, the lack of ...

Both CLD subtypes showed lower gene expression associated with fatty acid ... Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development, Journal ...